Gentian Diagnostics ASA (OSL:GENT)

Inozyme Pharma Revenue

Gentian Diagnostics ASA had revenue of 43.57M NOK in the quarter ending June 30, 2025, with 13.88% growth. This brings the company's revenue in the last twelve months to 163.38M, up 11.68% year-over-year. In the year 2024, Gentian Diagnostics ASA had annual revenue of 152.07M with 12.52% growth.

• Revenue (ttm): 163.38M
• Revenue Growth: +11.68%
• P/S Ratio: 5.59
• Revenue / Employee: 2.59M
• Employees: 63
• Market Cap: 913.00M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	152.07M	16.92M	12.52%
Dec 31, 2023	135.15M	23.23M	20.76%
Dec 31, 2022	111.92M	11.91M	11.91%
Dec 31, 2021	100.01M	21.13M	26.78%
Dec 31, 2020	78.88M	23.50M	42.43%